Reproducibility in biomarker research and clinical development : a global challenge by Scherer, Andreas
Biomark. Med. (Epub ahead of print) ISSN 1752-0363
part of
Editorial
10.2217/bmm-2017-0024 © 2017 Future Medicine Ltd
Biomark. Med.
Editorial 2017/03/30
11
4
2017
First draft submitted: 25 January 2017; Accepted for publication: 8 February 2017; 
Published online: 14 March 2017
Keywords:  biomarkers • consortia • reproducibility
According to a recent survey conducted by 
the journal Nature, a large percentage of 
scientists agrees we live in times of irrepro-
ducibility of research results [1]. They believe 
that much of what is published just cannot be 
trusted. While the results of the survey may 
be biased toward respondents with interest 
in the area of reproducibility, a concern is 
recognizable. Goodman et al. discriminate 
between different aspects of reproducibility 
and dissect the term into ‘material repro-
ducibility’ (provision of sufficient informa-
tion to enable repetition of the procedures), 
‘results reproducibility’ (obtaining the same 
results from an independent study; formerly 
termed ‘replicability’) and ‘inferential repro-
ducibility’ (drawing the same conclusions 
from separate studies) [2]. The validity of 
data is threatened by many issues, among 
others by poor utility of public information, 
poor protocols and design, lack of standard 
analytical, clinical practices and knowledge, 
conflict of interest and other biases, as well as 
 publication strategy.
Publication bias
In 2007, Kyzas et al. found that almost all 
1915 articles on cancer prognostic markers 
he looked at reported statistically significant 
positive associations [3]. Only about 1.4% of 
the articles were fully negative. The observed 
strong bias makes it very difficult to select and 
focus on promising biomarkers for follow-
up studies. When Tzoulaki et al. analyzed 
PubMed entries for meta-analyses of cardio-
vascular biomarkers (excluding those that are 
part of the Framingham Study), they found 
an excess of ‘positive’ results [4]. Reasons for 
‘selective analysis reporting bias’ are multiple 
hypothesis testing and certainly the degree of 
freedom that investigators have [5], for exam-
ple, a study is conducted without hypo theses, 
or the hypothesis is changed during the 
study to find something ‘positive’ (hypothe-
sis rescue bias). True ‘negative’ reports are 
rare, but important, such as the report on 
negative MRI biomarkers in the presence 
of strong tumor response to targeted cancer 
therapeutics by Boult et al. [6]. Furthermore, 
incomplete reporting of studies makes it 
hard to estimate their value. McShane has 
called for improvement of quality, complete-
ness and transparency of reporting of tumor 
biomarker studies to enhance their clinical 
utility [7]. Study preregistration is an interest-
ing concept which has recently been devel-
oped and adopted by a number of journals 
([8,9]). Under this strategy, the researcher 
submits the hypothesis and a research plan 
to the journal, where it is peer reviewed. 
Upon acceptance, the researcher has ease of 
mind that his manuscript will be accepted, 
no matter whether the outcome is positive 
or negative, as long as he/she adheres to the 
original project plan and passes a second 
review. In 2011, Andre et al. have proposed 
a registry for biomarker studies which would 
include details on the patient characteris-
tics, biomarkers tested and results [10]. One 
may expand on this idea by implementing a 
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preregistration database for clinical biomarker studies 
including the original hypothesis and its justification, 
as is done for therapeutic trials [11]. This could be done 
even on university/laboratory level, where biomarker 
studies (or any experiment for that matter) could be 
registered and locked. In fact, preregistration has been 
viewed as one of the ways out of the reproducibility 
crisis in the Nature survey mentioned earlier. In addi-
tion, the Nature survey respondents favor other ways to 
address the reproducibility crisis, for example, experi-
ment standardization, better training and mentor-
ing, and increasing the role of journals and funders 
in demanding thorough experiment design and result 
documentation and developing better reward systems 
for reproducibility studies. These are very important 
aspects and deserve thorough discussion and actions in 
the future. In my opinion, locking experiment design 
and hypothesis is important, and should be part of the 
implementation of academia quality system, similar to 
what already exists in industry. The Global Biological 
Standards Institute has linked the lack of such a system 
in academia to the reproducibility issue in academic 
research [12]. Implementation of an academic quality 
system will contribute to a better understanding of and 
trust in the quality and validity of research results com-
ing from academia which industry largely builds on 
these days. By focusing on quality-ensured data from 
academia, industry should be able to reduce not only 
waste of time and money, but also limit  unnecessary 
patient discomfort and suffering.
Standardization & harmonization efforts
Standardization efforts cannot be done in isolation if 
they are to reach public acceptance. Working in teams 
and in collaboration with other stakeholders, such as 
public–private partnerships or research consortia, pro-
vides a platform for exchange of ideas, analytical meth-
ods and better visibility to the stakeholders, than single 
laboratories can achieve. In the field of clinical bio-
marker development, method, material (e.g., cells and 
antibodies, but also software), and reporting standard-
ization, identification of markers, validation, and appli-
cation of biomarkers are so demanding processes that 
collaborations are vital [13]. For instance, develop ment 
of biomarkers for monitoring the success of personal-
ized interventions, a single, isolated organization will 
not be able to handle all operations. Through establish-
ing such collaborations and consortia, it is possible to 
obtain expert advise in areas, that a single investigator 
would otherwise not have easily access to when work-
ing in isolation. With good management, a consortium 
can address many aspects of reproducibility and gener-
ate new, relevant data and working hypotheses at the 
same time. Controlled application and comparison of 
methodologies, the development of standard operat-
ing procedures, preregistration and locking of hypo-
theses, and the potential to develop guidelines are only 
some of the benefits over working within an isolated 
laboratory. One example of such a collaboration is the 
US FDA initiated and -led community-wide effort 
for microarray quality control (MAQC, [14]), which 
started in 2005 to address the lack of guidelines and 
knowledge around the performance of microarray gene 
expression technologies. Teams from the USA, Europe, 
Asia and Australia came together to discuss and work 
on generating and analyzing high-throughput data. To 
address the question whether microarray gene expres-
sion data could be used as surrogate bio markers of clin-
ical end points, the analysis pipelines were designed 
and presented to a steering committee before the data 
analysis resumed, and locked for the rest of the study. 
Ideas and suggestions were shared among the analysis 
teams [15]. Meanwhile the MAQC has moved into the 
next-generation sequencing technology area and has 
assessed the reproducibility of technology platforms in 
the field of RNAseq [16] and recently in the genome 
sequencing, for example, for patient stratification 
(MAQCIV/SEQC2) [17]. Results and guidelines com-
ing out of the MAQC/SEQC are valuable for the FDA 
and investigators alike, to evaluate the validity of data 
coming from the genomics community.
Training
Nearly 90% of respondents of the Nature survey said 
they and the system would benefit from better train-
ing and mentorship [1]. I believe that all stakeholders 
involved in translational research, including inves-
tigators and funders, would benefit from objective 
mentor ship and advice. Over recent years, the Euro-
pean Infrastructure for Translational Medicine (EAT-
RIS) has taken on an additional role of a third-party 
advisory body to all stakeholders involved in trans-
lational research, including biomarker development. 
For instance, through the EATRIS expert panel of 
academic and clinical researchers and in response to 
the depth of the evaluation requirements of funding 
applications, EATRIS provides assessment of the clini-
cal need addressed in a project proposal, identifies the 
relevant translational tools and facilities for optimal 
data generation, the clarity of the vision of the end 
product, the IP clarity and the regulatory pipeline [18]. 
These services provide tools to reduce research waste 
and toward improved use of public funding. To further 
address burning issues in the area of translational medi-
cine, EATRIS with its more than 80 academic member 
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centers in 12 European states has realized the necessity 
of higher-grade collaborations across the globe. The 
‘Global Collaboration’, involving the NIH National 
Center for Advancing Translational Science, USA; [,19], 
Therapeutic Innovation Australia, AU; [20], MRC Tech-
nology (UK; [21]), EATRIS [22] and Center for Drug 
Research and Development; [23], is a novel endeavor to 
jointly utilize complementary expertise from all areas in 
translational research, with the goal of expediting the 
development of quality therapeutic interventions, and 
focus on exploring the criteria for reproducibility of key 
technologies in biomedical research [24]. 
Conclusion
At large, the current system of science is determined by 
financial aspects and a pressure to publish on scientists 
and journals alike. Funders are often overwhelmed by 
the sheer number of applications and may tend toward 
accepting overclaiming proposals.
Literally, we cannot afford wasting time and 
resources on false positives or false negatives. Under-
standing the relationship between method and inter-
pretation reproducibility with all its implications in 
statistics and clinical knowledge will be essential. We 
need to improve training in the necessity of ensuring 
data and reporting quality for successful translational 
and biomarker research, demand and create formal 
quality systems for academic research and encourage 
active participation in international collaborations. 
Adherence to reporting guidelines must be required, 
not only recommended. Through activities of organi-
zations, such as EATRIS, funders can get support in 
shortlisting applications, and investigators can strongly 
improve the quality of their applications by getting 
access to external, objective expertise in all areas of 
translational research.
It is time for changes and we need to act in order 
to save cost, time and, most importantly, human lives.
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